← Back to opportunities

Molecubes Preclinical SPECT Imager

MEDICINES DISCOVERY CATAPULT LIMITED

Buyer Contact Info

Buyer Name: MEDICINES DISCOVERY CATAPULT LIMITED

Buyer Address: Block 35g, Mereside Alderley Park, Macclesfield, UKD62, SK10 4ZF, United Kingdom

Contact Email: procurement@md.catapult.org.uk

Status
complete
Procedure
direct
Value
350000.0 GBP
Published
22 Sep 2025, 09:51
Deadline
n/a
Contract Start
01 Oct 2025, 23:00
Contract End
02 Jan 2027, 23:59
Category
n/a
CPV
38000000 - Laboratory, optical and precision equipments (excl. glasses)
Region
n/a
Awarded To
SOUTHERN SCIENTIFIC LIMITED
Official Source
Open Find a Tender

Description

MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications. These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow. SPECT imaging enables biodistribution studies for isotopes that PET cannot support. This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scientific and clinical needs. We have a clear opportunity to address this gap by introducing SPECT and CT capability through the phased procurement of the SPECT Cube module, followed by an upgrade to the advanced SPECT Cube 2.0 platform. This will allow MDC to meet rising diagnostic demand, align with industry standards, and maintain clinical competitiveness.

Linked Documents

No linked documents found for this notice.

Opportunity Context

Lots

Lot 1 Status: complete

Documents

Document Description: Not published

Raw Notice JSON

Expand raw payload
{
  "awards": [
    {
      "aboveThreshold": true,
      "contractPeriod": {
        "endDate": "2027-01-02T23:59:59Z",
        "startDate": "2025-10-02T00:00:00+01:00"
      },
      "documents": [
        {
          "datePublished": "2025-09-22T10:51:02+01:00",
          "description": "Transparency notice on Find a Tender",
          "documentType": "awardNotice",
          "format": "text/html",
          "id": "058392-2025",
          "noticeType": "UK5",
          "url": "https://www.find-tender.service.gov.uk/Notice/058392-2025"
        }
      ],
      "id": "1",
      "items": [
        {
          "additionalClassifications": [
            {
              "description": "Laboratory, optical and precision equipments (excl. glasses)",
              "id": "38000000",
              "scheme": "CPV"
            }
          ],
          "deliveryAddresses": [
            {
              "country": "GB",
              "countryName": "United Kingdom",
              "region": "UKD"
            }
          ],
          "id": "1",
          "relatedLot": "1"
        }
      ],
      "mainProcurementCategory": "goods",
      "milestones": [
        {
          "dueDate": "2025-10-02T23:59:59+01:00",
          "id": "1",
          "status": "scheduled",
          "type": "futureSignatureDate"
        }
      ],
      "relatedLots": [
        "1"
      ],
      "status": "pending",
      "suppliers": [
        {
          "id": "GB-COH-01800317",
          "name": "SOUTHERN SCIENTIFIC LIMITED"
        }
      ],
      "value": {
        "amount": 350000,
        "amountGross": 420000,
        "currency": "GBP"
      }
    }
  ],
  "buyer": {
    "id": "GB-COH-09928547",
    "name": "MEDICINES DISCOVERY CATAPULT LIMITED"
  },
  "date": "2025-09-22T10:51:02+01:00",
  "id": "058392-2025",
  "initiationType": "tender",
  "language": "en",
  "ocid": "ocds-h6vhtk-059ecc",
  "parties": [
    {
      "additionalIdentifiers": [
        {
          "id": "PJPQ-6911-DQYY",
          "scheme": "GB-PPON"
        }
      ],
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "Macclesfield",
        "postalCode": "SK10 4ZF",
        "region": "UKD62",
        "streetAddress": "Block 35g, Mereside Alderley Park"
      },
      "contactPoint": {
        "email": "procurement@md.catapult.org.uk"
      },
      "details": {
        "classifications": [
          {
            "description": "Public authority - sub-central government",
            "id": "publicAuthoritySubCentralGovernment",
            "scheme": "UK_CA_TYPE"
          }
        ]
      },
      "id": "GB-COH-09928547",
      "identifier": {
        "id": "09928547",
        "scheme": "GB-COH"
      },
      "name": "MEDICINES DISCOVERY CATAPULT LIMITED",
      "roles": [
        "buyer"
      ]
    },
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "Henfield",
        "postalCode": "BN5 9SL",
        "region": "UKJ28",
        "streetAddress": "Scientific House Henfield Business Park"
      },
      "contactPoint": {
        "email": "tender@southernscientific.co.uk"
      },
      "details": {
        "scale": "sme",
        "url": "https://www.southernscientific.co.uk",
        "vcse": false
      },
      "id": "GB-COH-01800317",
      "identifier": {
        "id": "01800317",
        "scheme": "GB-COH"
      },
      "name": "SOUTHERN SCIENTIFIC LIMITED",
      "roles": [
        "supplier"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "description": "MDC\u0027s current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications. \nThese include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow.\nSPECT imaging enables biodistribution studies for isotopes that PET cannot support. This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scientific and clinical needs. We have a clear opportunity to address this gap by introducing SPECT and CT capability through the phased procurement of the SPECT Cube module, followed by an upgrade to the advanced SPECT Cube 2.0 platform. This will allow MDC to meet rising diagnostic demand, align with industry standards, and maintain clinical competitiveness.",
    "documents": [
      {
        "description": "Not published",
        "documentType": "conflictOfInterest",
        "id": "conflictOfInterest"
      }
    ],
    "id": "ocds-h6vhtk-059ecc",
    "legalBasis": {
      "id": "2023/54",
      "scheme": "UKPGA",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
    },
    "lots": [
      {
        "id": "1",
        "status": "complete"
      }
    ],
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "The system supports high-energy collimators and emerging radionuclides such as 212-Pb and 203-Pb, which are critical for MDC\u0027s research pipeline and are compatible with existing MDC equipment which enables an integrated system allowing simultaneous imaging of SPECT PET and CT imaging in one work flow.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "singleSuppliersTechnicalReasons"
      }
    ],
    "status": "complete",
    "title": "Molecubes Preclinical SPECT Imager"
  }
}